Evidence map›Paper›PMID 34102299›Full record

ArticleInternational journal of radiation oncology, biology, physics2021

Forecasting Individual Patient Response to Radiation Therapy in Head and Neck Cancer With a Dynamic Carrying Capacity Model.

Mohammad U Zahid, Nuverah Mohsin, Abdallah S R Mohamed, Jimmy J Caudell, Louis B Harrison, Clifton D Fuller, Eduardo G Moros, Heiko Enderling

Open access · greenAbstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Identifiability and model selection frameworks for models of high-grade glioma response to chemoradiation.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mohammad U ZahidDepartment of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Nuverah MohsinDepartment of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida; Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, Florida.
Abdallah S R MohamedDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jimmy J CaudellDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Louis B HarrisonDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Clifton D FullerDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Eduardo G MorosDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Heiko EnderlingDepartment of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida; Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida. Electronic address: heiko.enderling@moffitt.org.
Moffitt Cancer Center · USThe University of Texas MD Anderson Cancer Center · USNova Southeastern University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2002 to 2012
$26.1M
Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac deviceR01DE028290 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHRISTODOULEAS, JOHN PAUL, FULLER, CLIFTON DAVID · 2019 to 2023
$4.3M
Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapyU01CA244100 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ENDERLING, HEIKO, PILON-THOMAS, SHARI · 2020 to 2025
$2.6M
imaging Radiation-Associated Dysphagia (iRAD)R01CA218148 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FULLER, CLIFTON DAVID, HUTCHESON, KATHERINE ARNOLD · 2017 to 2019
$810k
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA097007NCI NIH HHS R01 CA218148NCI NIH HHS U01 CA244100NIDCR NIH HHS R01 DE028290
6 · The paper itself

Abstract

purposeTo model and predict individual patient responses to radiation therapy. METHODS AND MATERIALS: We modeled tumor dynamics as logistic growth and the effect of radiation as a reduction in the tumor carrying capacity, motivated by the effect of radiation on the tumor microenvironment. The model was assessed on weekly tumor volume data collected for 2 independent cohorts of patients with head and neck cancer from the H. Lee Moffitt Cancer Center (MCC) and the MD Anderson Cancer Center (MDACC) who received 66 to 70 Gy in standard daily fractions or with accelerated fractionation. To predict response to radiation therapy for individual patients, we developed a new forecasting framework that combined the learned tumor growth rate and carrying capacity reduction fraction (δ) distribution with weekly measurements of tumor volume reduction for a given test patient to estimate δ, which was used to predict patient-specific outcomes.

resultsThe model fit data from MCC with high accuracy with patient-specific δ and a fixed tumor growth rate across all patients. The model fit data from an independent cohort from MDACC with comparable accuracy using the tumor growth rate learned from the MCC cohort, showing transferability of the growth rate. The forecasting framework predicted patient-specific outcomes with 76% sensitivity and 83% specificity for locoregional control and 68% sensitivity and 85% specificity for disease-free survival with the inclusion of 4 on-treatment tumor volume measurements.

conclusionsThese results demonstrate that our simple mathematical model can describe a variety of tumor volume dynamics. Furthermore, combining historically observed patient responses with a few patient-specific tumor volume measurements allowed for the accurate prediction of patient outcomes, which may inform treatment adaptation and personalization.

Indexed as

Conservation of Natural ResourcesHead and Neck NeoplasmsDisease-Free SurvivalDose Fractionation, RadiationHumansTumor BurdenTumor Microenvironment

Identifiers

PMID34102299
PMCPMC8463501
OpenAlexW3171645542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.